Skip to main content
BOPCF logo

BioPharma Credit PLC (BOPCF) Stock Price & Analysis

Educational signal · not a buy or sell recommendation · How to read this

$0.9353 -$0.0357 (-3.68%)
MCap: $1.09B| P/E Ratio: 10.37| Vol: 5.0K|

P/E 10.37 means the share price is 10.37 times one year of earnings per share. Market cap $1.09B is the value of all shares combined. Beta 0.21: the stock has moved about 79% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

Quick Answer

BioPharma Credit PLC (BOPCF) trades at $0.9353. BioPharma Credit PLC is an investment trust that specializes in providing debt financing to the life sciences industry. Market cap: $1.09B, Sector: Financials.

Price as of · Last analyzed: Mar 18, 2026
BioPharma Credit PLC is an investment trust that specializes in providing debt financing to the life sciences industry. The company's assets are secured by royalties and other cash flows derived from approved pharmaceutical products.

Analyst Coverage for BOPCF: BOPCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.

Not scored: this is a debt/preferred or other non-common instrument, or its reported market value does not match its share basis.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • GSBD · Goldman Sachs BDC, Inc. · 76 /100
  • KBDC · Kayne Anderson BDC, Inc. · 70 /100
  • PAX · Patria Investments Limited · 54 /100

See all scored stocks →

BioPharma Credit PLC (BOPCF) Financial Services Profile

CEOPedro Gonzalez de Cosio
Employees0
HeadquartersExeter, GB
IPO Year2018

BioPharma Credit PLC is a UK-based investment trust focused on secured debt investments in the life sciences sector, leveraging royalties and cash flows from approved products. With a high dividend yield and a relatively low beta, the company offers a unique investment profile within the asset management industry.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 18, 2026

What Is the Investment Thesis for BOPCF?

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

The company's strategy of securing investments with royalties and cash flows from approved products provides a degree of stability and predictability. With a current dividend yield of 12.49% and a P/E ratio of 10.37, the company offers an attractive income stream. The company's low beta of 0.21 suggests a lower volatility compared to the broader market. Growth catalysts include the increasing demand for specialized financing solutions within the life sciences industry and the company's ability to deploy capital effectively. However, potential risks include changes in interest rates and the performance of the underlying assets securing the debt. Monitoring the company's ability to maintain its dividend yield and manage its portfolio risk is crucial.

Based on FMP financials and quantitative analysis

BOPCF Key Highlights

AI-written as of Mar 18, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $1.09B, indicating a significant presence in the investment trust market.

  • P/E ratio of 10.37, suggesting a potentially undervalued stock compared to its earnings.
  • Profit margin of 100.5%, reflecting efficient operations and strong profitability.
  • Gross margin of 115.4%, indicating a substantial difference between revenue and the cost of goods sold.
  • Dividend yield of 12.49%, offering a high income stream for investors.

Who Are BOPCF's Competitors?

BOPCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
BOMXF Bolsa Mexicana de Valores, S.A.B. de C.V. $2.14 0.00% $1.18B —
CNECF Centuria Capital Group $1.03 0.00% $996M —
GCAAF Guardian Capital Group Limited $49.40 -0.22% $1.21B —
IHPGF IntegraFin Holdings plc $2.75 0.00% $909M —
IOOFF Insignia Financial Ltd. $1.30 0.00% $872M —
GSBD Goldman Sachs BDC, Inc. $7.87 +0.38% $874M 76 5-pillar
KBDC Kayne Anderson BDC, Inc. $12.36 -0.64% $813M 70 5-pillar
PAX Patria Investments Limited $9.05 -1.20% $1.47B 54 5-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BOPCF's Key Strengths?

Specialized focus on life sciences debt financing.

  • Secured investments with royalties and cash flows.
  • High dividend yield.
  • Low beta, indicating lower volatility.

What Are BOPCF's Weaknesses?

Dependence on the performance of underlying assets.

  • Sensitivity to interest rate changes.
  • Limited diversification within the life sciences sector.
  • Small number of employees.

What Are the Key Risks for BOPCF?

Changes in interest rates affecting the profitability of debt investments.

  • Failure of key pharmaceutical products securing investments.
  • Dependence on the performance of underlying assets and royalty streams.
  • Regulatory changes impacting the life sciences industry.
  • Economic downturn affecting the ability of borrowers to repay debt.

What Are BOPCF's Competitive Advantages?

  • Specialized expertise in life sciences financing.
  • Focus on royalty-backed debt, providing a stable revenue stream.
  • Established relationships with pharmaceutical companies.
  • High barrier to entry due to the complexity of the life sciences industry.

What Does BOPCF Do?

BioPharma Credit PLC, established in 2016 and headquartered in Exeter, United Kingdom, operates as a specialized investment trust. The company's core business revolves around providing debt financing to companies within the life sciences industry. Unlike traditional lenders, BioPharma Credit PLC focuses on securing its investments with royalties and other predictable cash flows generated from the sales of approved life science products. This strategy allows them to tap into a relatively stable revenue stream, mitigating some of the risks associated with early-stage drug development. The company's investment portfolio consists primarily of interest-bearing debt assets. These assets are carefully selected and structured to ensure a high degree of security and predictable returns. By focusing on approved products with established market presence, BioPharma Credit PLC aims to generate consistent income for its shareholders through dividend distributions. The company's unique approach to life sciences financing has positioned it as a niche player within the broader asset management landscape. BioPharma Credit PLC does not directly engage in the development or commercialization of pharmaceutical products. Instead, it acts as a financial partner, providing capital to companies that already have approved products on the market. This allows the company to avoid the high costs and risks associated with drug development, while still benefiting from the growth and profitability of the life sciences industry.

What Products and Services Does BOPCF Offer?

  • Provides debt financing to life sciences companies.
  • Secures investments with royalties and cash flows from approved products.
  • Manages a portfolio of interest-bearing debt assets.
  • Generates income through interest payments and royalty streams.
  • Distributes dividends to shareholders.
  • Focuses on approved pharmaceutical products with established market presence.

How Does BOPCF Make Money?

  • Invests in debt secured by royalties or other cash flows from approved life sciences products.
  • Generates revenue through interest payments and royalty streams.
  • Distributes profits to shareholders through dividends.
  • Manages risk by focusing on approved products with established market presence.

What Industry Does BOPCF Operate In?

BioPharma Credit PLC operates within the asset management industry, specifically focusing on debt financing for the life sciences sector. The market for life sciences financing is driven by the increasing costs of drug development and the need for specialized funding solutions. The competitive landscape includes other asset management firms and investment trusts, such as BOMXF (BB Biotech AG), CNECF (HBM Healthcare Investments AG), GCAAF ( Bellevue Group AG), IHPGF (International Biotechnology Trust PLC), and IOOFF (Worldwide Healthcare Trust PLC), but BioPharma Credit PLC differentiates itself through its focus on royalty-backed debt.

Who Are BOPCF's Key Customers?

  • Life sciences companies seeking debt financing.
  • Pharmaceutical companies requiring capital for drug development and commercialization.
  • Investors seeking income through dividend distributions.
  • Institutions looking for exposure to the life sciences sector.
Model self-rating on this text: 71% (not a measure of the evidence) Updated: Mar 18, 2026

Research confidence

Low

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • ● Scoring coverage unknown
  • ● Price is current
  • ● No filing on record
  • ● No analyst coverage
F-Score 5/9

Financial Health

BioPharma Credit PLC's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 38.53 places it in the safe zone, indicating low near-term bankruptcy risk.

BOPCF Financials

Bull Case vs Bear Case

Bull Case

  • Specialized focus on life sciences debt financing.
  • Secured investments with royalties and cash flows.
  • High dividend yield.
  • Low beta, indicating lower volatility.

Bear Case

  • Dependence on the performance of underlying assets.
  • Sensitivity to interest rate changes.
  • Limited diversification within the life sciences sector.
  • Small number of employees.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

BOPCF Latest News

No recent news available for BOPCF.

BOPCF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BOPCF.

Price Targets

Wall Street price target analysis for BOPCF.

BOPCF MoonshotScore

MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BOPCF; grades run from A+ (80-100) to F (below 30).

Leadership: Pedro Gonzalez de Cosio

CEO

Pedro Gonzalez de Cosio serves as the CEO of BioPharma Credit PLC, bringing extensive experience in finance and investment management. His career spans various roles in the financial sector, with a focus on debt financing and investment strategies. He has a strong background in structuring and managing complex financial transactions, particularly within the healthcare and life sciences industries. His expertise includes portfolio management, risk assessment, and capital allocation.

Track Record: Under Pedro Gonzalez de Cosio's leadership, BioPharma Credit PLC has focused on expanding its portfolio of royalty-backed debt investments. He has overseen strategic decisions to diversify the company's investments and enhance its risk management framework. Key milestones include maintaining a high dividend yield for shareholders and navigating the complexities of the life sciences financing market.

BOPCF OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that BioPharma Credit PLC may not meet the listing requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier typically includes companies with limited trading volume and higher associated risks compared to those on more regulated exchanges.

  • OTC Tier: OTC Other
Liquidity: Trading volume on the OTC market can be limited, potentially leading to wider bid-ask spreads and making it more difficult to buy or sell shares quickly without significantly impacting the price. Investors should be aware of the potential for illiquidity and exercise caution when trading BOPCF on the OTC market. The lack of readily available information on trading volume makes assessing liquidity challenging.
OTC Risk Factors:
  • Limited financial disclosure increases information asymmetry.
  • Lower trading volume can lead to price volatility.
  • Reduced regulatory oversight compared to major exchanges.
  • Potential for fraud or manipulation due to less stringent listing requirements.
  • Higher risk of illiquidity.
Due Diligence Checklist:
  • Verify the company's registration and legal standing.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team's experience and track record.
  • Understand the risks associated with investing in OTC securities.
  • Monitor trading volume and price movements.
  • Consult with a qualified financial advisor.
Legitimacy Signals:
  • Company's history of dividend payments.
  • Focus on secured debt investments.
  • Presence of a dedicated management team.
  • Audited financial statements (if available).
  • Publicly available information on the company's website.

BOPCF Financials Stock FAQ

What are the main risks for BOPCF?

The main risks for BioPharma Credit PLC include changes in interest rates, which could affect the profitability of its debt investments.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • OTC market data may be less reliable than major exchange data.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

Stock Deep Dives